Skip to main content

Table 2 Treatment regimens in Arm B

From: STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

A. Doses in modified FOLFOX7-bevacizumab
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 100 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Folinic Acid 400 mg/m2 (leucovorin, racemic or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU continuous infusion 3000 mg/m2, 46 h IV infusion
B. Doses in modified XELOX-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30–60 min IV infusion
H + 1 Oxaliplatin 100 mg/m2 in 250 ml glucose 5 %, 2 h infusion
Day 1-8 Capecitabine 1250–1500 mg/m2 bid, day 1 (in the evening) to day 8 (in the morning)
C. Doses in simplified LV5FU2-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Folinic acid 400 mg/m2 (leucovorin, racemic or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
D. Doses in capecitabine-bevacizumab regimen
H0 Bevacizumab 7.5 mg/kg, 30 min IV infusion
Day 1-14 Capecitabine 1000 mg/m2 x twice daily (on days 1 to 14; 28 doses)
E. Doses in modified FOLFIRI3-bevacizumab regimen
H0 (Day 1) Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Irinotecan 90 mg/m2 in 250 ml glucose 5 %, 1 h IV infusion
Folinic Acid 400 mg/m2 (leucovorin, racemic or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
H + 46 (Day 3) Irinotecan 90 mg/m2, 1 h IV infusion
F. Doses in FOLFIRI1-bevacizumab regimen
H0 Bevacizumab 5 mg/kg, 30 min IV infusion
H + 1 Irinotecan 180 mg/m2 in 250 ml glucose 5 %, 1 h IV infusion
Folinic acid 400 mg/m2 (leucovorin, racemic or L-form 200 mg/m2) in 250 ml glucose 5 % solution, 2 h IV infusion
H + 3 5FU bolus 400 mg/m2 in 100 ml glucose 5 % solution, 15 min IV infusion
H + 3.5 5FU continuous infusion 2400 mg/m2, 46 h IV infusion
G. Doses in cetuximab +/− irinotecan regimen
H0 Cetuximab, 400 mg/m2 /2 h IV infusion (first dose), then 250 mg/m2 /1 h at subsequent IV infusions, every week
or
Cetuximab 500 mg/m2 /2 h IV infusion (first dose), then 500 mg/m2 /1 h at subsequent IV infusions, every 2 weeks
H + 1 Irinotecan 180 mg/m2 in 250 ml glucose 5 %, 1 h IV infusion (optional)
H. Dose of panitumumab monotherapy
H0 Panitumumab, 6 mg/kg, 1 h IV infusion, every 2 weeks
  1. a. b Cycles every 2 weeks, during 6 cycles (3 months). c. Cycles every 2 weeks, until disease progression, CFI, unacceptable toxicity or withdrawal of consent. d. Cycles every 3 weeks, until disease progression, CFI, unacceptable toxicity or withdrawal of consent. e. Cycles every 2 weeks, until disease progression, unacceptable toxicity or withdrawal of consent. f. Cycles every 2 weeks, until disease progression, unacceptable toxicity or withdrawal of consent. g. Cetuximab every 1 or 2 weeks, until disease progression, unacceptable toxicity or withdrawal of consent. h. Cycles every two weeks, until disease progression, unacceptable toxicity or withdrawal of consent